(Q46949691)

26 December 2017

title

Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design (English)

1 reference

26 December 2017

1 reference

4

Henry Nasrallah

1 reference

26 December 2017

author name string

Frank Gianfrancesco

series ordinal

1

1 reference

26 December 2017

Jacqueline Pesa

series ordinal

2

1 reference

26 December 2017

Ruey-Hua Wang

series ordinal

3

1 reference

26 December 2017

publication date

1 March 2006

1 reference

26 December 2017

American Journal of Health-System Pharmacy

published in

1 reference

26 December 2017

volume

63

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

431-441

1 reference

26 December 2017

Consensus development conference on antipsychotic drugs and obesity and diabetes

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

New onset diabetes and atypical antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Atypical antipsychotics and hyperglycaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

New-onset diabetes and ketoacidosis with atypical antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

The effects of novel antipsychotics on glucose and lipid levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Atypical antipsychotics and weight gain--a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Glucose intolerance with atypical antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

The ethical problem of false positives: a prospective evaluation of physician reporting in the medical record

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Can we be certain of PRO accuracy and accountability? Inaccurate "report cards" generated by medicare claims data as a marker for laboratory testing in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Prevalence and correlates of diabetes in national schizophrenia samples.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Diabetes mellitus in schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Prevalence of diabetes in a manic-depressive population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Novel antipsychotics and new onset diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Schizophrenia and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

Drug-induced hyperglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050144

31 March 2020

Identifiers

DOI

10.2146/AJHP050144

1 reference

26 December 2017

1 reference

26 December 2017